Search

Your search keyword '"Morimoto M"' showing total 425 results
Start Over Author "Morimoto M" Search Limiters Peer Reviewed
425 results on '"Morimoto M"'

1. Comparison of the 2-Year Results of Photodynamic Therapy with Aflibercept and Aflibercept Monotherapy for Polypoidal Choroidal Vasculopathy

Author

Miyakubo T, Mukai R, Matsumoto H, Morimoto M, Takahashi M, Nagai K, Nakamura K, Hoshino J, and Akiyama H

Subjects
polypoidal choroidal vasculopathy, aflibercept, photodynamic therapy, treat-and-extend, macular atrophy, Ophthalmology, RE1-994
Abstract

Tomoko Miyakubo, Ryo Mukai, Hidetaka Matsumoto, Masahiro Morimoto, Maki Takahashi, Kazuki Nagai, Kosuke Nakamura, Junki Hoshino, Hideo Akiyama Department of Ophthalmology, Gunma University, Graduate School of Medicine, Maebashi, Gunma, JapanCorrespondence: Ryo Mukai, Department of Ophthalmology, Gunma University Graduate School of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma, 371-8511, Japan, Tel +81-27-220-8338, Fax +81-27-233-3841, Email rmukai@gunma-u.ac.jpPurpose: To compare the efficacies of photodynamic therapy (PDT) combined with intravitreal aflibercept (IVA) injections and IVA monotherapy using a treat-and-extend regimen (TAE) for treatment-naïve polypoidal choroidal vasculopathy (PCV).Patients and Methods: One hundred and nine eyes treated with PDT combined with IVA (PDT+IVA group: 51 eyes) or IVA monotherapy (IVA group: 58 eyes) were assessed for 2 years. The main outcome measures included best-corrected visual acuity (BCVA), central macular thickness (CMT), central choroidal thickness (CCT), number of IVA injections, and macular atrophy (MA). Polypoidal lesions before and after the loading phase were assessed using indocyanine green angiography.Results: In both groups, BCVA significantly improved after the loading phase and was maintained for 2 years. CMT and CCT were significantly reduced in both groups, without significant differences after 2 years between the groups (P=0.2708). The mean number of IVA injections in the IVA and PDT+IVA groups during the 2 years were 13.2± 3.3 and 12.7± 1.8, respectively, without a significant difference (P=0.06). The frequencies of MA expansion in the IVA and PDT+IVA groups during the 2 years were 25.9% and 33.4%, respectively, with no significant difference in the incidence (odds ratio: 1.40, P=0.4253). The ratios of polyp regression after the loading phase in the IVA and PDT+IVA groups were 55.2% and 94.1%, respectively, with a significant difference (P< 0.0001).Conclusion: PDT combined with IVA injections using a TAE regimen is effective for anatomical and visual function improvement, without a significant difference as compared to IVA monotherapy. It can facilitate complete regression of polyps with higher odds.Keywords: polypoidal choroidal vasculopathy, aflibercept, photodynamic therapy, treat-and-extend, macular atrophy

Published
2023

2. Safety and Efficacy of Lenvatinib Treatment in Child–Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis

Author

Ogushi K, Chuma M, Uojima H, Hidaka H, Numata K, Kobayashi S, Hirose S, Hattori N, Fujikawa T, Nakazawa T, Wada N, Iwasaki S, Fukushima T, Sano Y, Ueno M, Kawano K, Tsuruya K, Shomura M, Watanabe T, Matsunaga K, Kunishi Y, Saigusa Y, Irie K, Iwabuchi S, Kako M, Morimoto M, Kagawa T, Tanaka K, and Maeda S

Subjects
lenvatinib, tyrosine kinase inhibitor, hepatocellular carcinoma, child-pugh, adverse events, overall survival, Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Katsuaki Ogushi,1,* Makoto Chuma,1,* Haruki Uojima,2 Hisashi Hidaka,2 Kazushi Numata,1 Satoshi Kobayashi,3 Shunji Hirose,4 Nobuhiro Hattori,5 Tomoaki Fujikawa,6 Takahide Nakazawa,2 Naohisa Wada,2 Shuitirou Iwasaki,2 Taito Fukushima,3 Yusuke Sano,3 Makoto Ueno,3 Kuniyuki Kawano,3 Kota Tsuruya,4 Masako Shomura,4 Tsunamasa Watanabe,5 Kotaro Matsunaga,5 Yosuke Kunishi,7 Yusuke Saigusa,8 Kuniyasu Irie,9 Shogo Iwabuchi,6 Makoto Kako,10 Manabu Morimoto,3 Tatehiro Kagawa,4 Katsuaki Tanaka,11 Shin Maeda9 1Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan; 2Department of Gastroenterology, Internal Medicine, Kitasato University School of Medicine, Sagamihara, Japan; 3Hepatobiliary and Pancreatic Medical Oncology, Kanagawa Cancer Center Hospital, Yokohama, Japan; 4Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokai University School of Medicine, Isehara, Japan; 5Division of Gastroenterology and Hepatology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan; 6Department of Gastroenterology, Shonan Fujisawa General Hospital, Fujisawa, Japan; 7Department of Gastroenterology, Kanagawa Prefectural Ashigarakami Hospital, Kanagawa, Japan; 8Department of Biostatistics, Yokohama City University Graduate School of Medicine, Yokohama, Japan; 9Department of Gastroenterology, Yokohama City University Hospital, Yokohama, Japan; 10Department of Gastroenterology, Shonan Kamakura General Hospital, Kamakura, Japan; 11Gastroenterology Division, Hadano Red Cross Hospital, Hadano, Japan*These authors contributed equally to this workCorrespondence: Makoto Chuma Gastroenterological CenterYokohama City University Medical Center, 4-57 Urafune-Cho, Minami-Ku, Yokohama, Kanagawa 2320024, JapanTel +81 45 261 5656Fax +81 45 253 9955Email chuma@yokohama-cu.ac.jpPurpose: To assess the safety, efficacy and prognostic impact of clinical factors related to lenvatinib treatment in Child-Pugh class A (CP-A) and class B (CP-B) patients with unresectable hepatocellular carcinoma (u-HCC).Methods: Patients with u-HCC who were treated with lenvatinib at multiple centers in Japan were retrospectively analyzed for treatment outcomes according to their respective CP status. Radiological objective response (OR) was assessed using modified response evaluation criteria in solid tumors (mRECIST) guidelines.Results: Baseline demographic parameters were comparable between 126 (69.6%) patients with CP-A disease and 55 patients (30.4%) with CP-B disease. Frequency of lenvatinib-related adverse events, including decreased appetite (P=0.034), diarrhea (P=0.040), elevated serum bilirubin (P=0.016) and vomiting (P=0.009), were higher in CP-B than in CP-A patients. Relative dose intensity (RDI) was significantly higher in CP-A (0.69) than CP-B patients (0.50, P < 0.001). Furthermore, OR rate (44.0%) was markedly higher in CP-A5 patients as compared to CP-A6 (25.5%), CP-B7 (22.2%), and CP-B8 patients (5.3%), respectively (P=0.002). In multivariable analysis, performance status (0 vs 1, 2, P=0.026), CP class (A vs B, P=0.045) and RDI (≥ 0.7 vs < 0.7, P=0.034) were identified as factors associated with response to lenvatinib treatment. Overall survival (OS) at 12 months was significantly different between CP-A (66.3%) and CP-B patients (30.0%, P=0.002), and between CP 5– 7 (59.2%) and CP 8 patients (34.8%, P=0.003). In multivariable analysis, CP class (A vs B, P=0.007) and Barcelona clinic liver cancer (BCLC) stage (B vs C, P=0.002) were associated with OS following lenvatinib treatment.Conclusion: Lenvatinib treatment offers significant benefits in patients with good liver function in real-world practice. The various characteristics identified in this study might be helpful as clinical predictors of response to lenvatinib and survival in clinical practice. Further studies are required to address eligibility for lenvatinib treatment in CP 7 patients.Keywords: lenvatinib, tyrosine kinase inhibitor, hepatocellular carcinoma, Child-Pugh, adverse events, overall survival

Published
2020

3. Hybrid stars from a three-flavor NJL model with two kinds of tensor condensates

Author

Morimoto, M., Tsue, Y., da Providencia, J., Providencia, C., and Yamamura, M.

Subjects
High Energy Physics - Phenomenology, Nuclear Theory
Abstract

To obtain the equation of state of quark matter and construct hybrid stars, we calculate the thermodynamic potential in the three-flavor Nambu-Jona-Lasinio model including the tensor-type four-point interaction and the Kobayashi-Maskawa-'t Hooft interaction. To construct the hybrid stars, it is necessary to impose the beta-equilibrium and charge neutrality conditions on the system. It is shown that tensor condensed phases appear at large chemical potential. Under the possibility of the existence of the tensor condensates, the relationship between the radius and mass of hybrid stars is estimated., Comment: 22 pages, 12 figures

Published
2020
Full Text
View/download PDF

4. Non-zero tensor condensates in cold quark matter within the three-flavor Nambu-Jona-Lasinio model with the Kobayashi-Maskawa-'t Hooft interaction

Author

Kagawa, A., Morimoto, M., Tsue, Y., da Providencia, J., Providencia, C., and Yamamura, M.

Subjects
High Energy Physics - Phenomenology, Nuclear Theory
Abstract

The possible formation of tensor condensates originated from a tensor-type interaction between quarks is investigated in the three-flavor Nambu-Jona-Lasinio model including the Kobayashi-Maskawa-'t Hooft interaction, which leads to flavor mixing. It is shown that independent two tensor condensates appear and a tensor condensate related to the strange quark easily occurs by the effect of the flavor mixing compared with one related to light quarks. Also, it is shown that the tensor condensate related to the strange quark appears at a slightly smaller chemical potential if the Kobayashi-Maskawa-'t Hooft interaction is included, due to the flavor mixing effect. It is also shown that the two kinds of tensor condensates may coexist in a certain quark chemical potential due to the flavor mixing., Comment: 13 pages, 9 figures, using PTPTeX. arXiv admin note: text overlap with arXiv:1910.03221

Published
2020
Full Text
View/download PDF

5. Spin polarizations under a pseudovector interaction between quarks with the Kobayashi-Maskawa-'t Hooft term in high density quark matter

Author

Morimoto, M., Tsue, Y., da Providencia, J., Providencia, C., and Yamamura, M.

Subjects
High Energy Physics - Phenomenology, Nuclear Theory
Abstract

A possibility of a quark spin polarization originated from a pseudovector condensate is investigated in the three-flavor Nambu-Jona-Lasinio model with the Kobayashi-Maskawa-'t Hooft interaction which leads to flavor mixing. It is shown that a pseudovector condensate related to the strange quark easily occurs compared with pseudovector condensate related to light quarks. Further, it is shown that the pseudovector condensate related to the strange quark appears at a slightly small chemical potential by the effect of the flavor mixing due to the Kobayashi-Maskawa-'t Hooft interaction., Comment: 14 pages, 14 figures

Published
2019
Full Text
View/download PDF

6. Spontaneous magnetization under a pseudovector interaction between quarks in high density quark matter

Author

Morimoto, M., Tsue, Y., da Providencia, J., Providencia, C., and Yamamura, M.

Subjects
High Energy Physics - Phenomenology, Nuclear Theory
Abstract

Spontaneous magnetization and magnetic susceptibility originated from the pseudovector-type four-point interaction between quarks are calculated in quark matter with zero temperature and finite quark chemical potential by using the two-flavor Nambu-Jona-Lasinio model. It is shown that both the chiral condensate and spin polarized condensate coexist in a narrow region of the quark chemical potential. And then, it is also shown that, in this narrow region, the spontaneous magnetization appears. Also, the magnetic susceptibility due to quarks with the positive energy is evaluated in the spin polarized phase., Comment: 15 pages, 2 figures

Published
2018
Full Text
View/download PDF

8. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

Author

Bang, Y-J, Bendell, J, Chao, Y, Chen, J-S, Chung, H C, Davis, S L, Dev, A, Gane, E, George, B, He, A R, Hochster, H, Hsu, C-H, Ikeda, M, Lee, J, Lee, M, Mahipal, A, Manji, G, Morimoto, M, Numata, K, Pishvaian, M, Qin, S, Ryan, D, Ryoo, B-Y, Sasahira, N, Stein, S, Strickler, J, Tebbutt, N, Lee, Michael S, Ryoo, Baek-Yeol, Hsu, Chih-Hung, Numata, Kazushi, Stein, Stacey, Verret, Wendy, Hack, Stephen P, Spahn, Jessica, Liu, Bo, Abdullah, Heba, Wang, Yulei, He, Aiwu Ruth, and Lee, Kyung-Hun

Published
2020
Full Text
View/download PDF

9. Overview and Initial Results of the Very Long Baseline Interferometry Space Observatory Programme

Author

Hirabayashi, H., Hirosawa, H., Kobayashi, H., Murata, Y., Edwards, P. G., Fomalont, E. B., Fujisawa, K., Ichikawa, T., Kii, T., Lovell, J. E. J., Moellenbrock, G. A., Okayasu, R., Inoue, M., Kawaguchi, N., Kameno, S., Shibata, K. M., Asaki, Y., Bushimata, T., Enome, S., Horiuchi, S., Miyaji, T., Umemoto, T., Migenes, V., Wajima, K., Nakajima, J., Morimoto, M., Ellis, J., Meier, D. L., Murphy, D. W., Preston, R. A., Smith, J. G., Tingay, S. J., Traub, D. L., Wietfeldt, R. D., Benson, J. M., Claussen, M. J., Flatters, C., Romney, J. D., Ulvestad, J. S., D'Addario, L. R., Langston, G. I., Minter, A. H., Carlson, B. R., Dewdney, P. E., Jauncey, D. L., Reynolds, J. E., Taylor, A. R., McCulloch, P. M., Cannon, W. H., Gurvits, L. I., Mioduszewski, A. J., Schilizzi, R. T., and Booth, R. S.

Published
1998

13. Design of ITER vacuum vessel in-wall shielding

Author

Wang, X., Ioki, K., Morimoto, M., Choi, C.H., Utin, Y., Sborchia, C., TaiLhardat, O., Mille, B., Terasawa, A., Gribov, Y., Barabash, V., Polunovskiy, E., Dani, S., Pathak, H., Raval, J., Liu, S., Lu, M., and Du, S.

Published
2014
Full Text
View/download PDF

14. Detection of copy number variations in epilepsy using exome data

Author

Tsuchida, N., Nakashima, M., Kato, M., Heyman, E., Inui, T., Haginoya, K., Watanabe, S., Chiyonobu, T., Morimoto, M., Ohta, M., Kumakura, A., Kubota, M., Kumagai, Y., Hamano, S.‐I., Lourenco, C.M., Yahaya, N.A., Chʼng, G.‐S., Ngu, L.‐H., Fattal‐Valevski, A., Weisz Hubshman, M., Orenstein, N., Marom, D., Cohen, L., Goldberg‐Stern, H., Uchiyama, Y., Imagawa, E., Mizuguchi, T., Takata, A., Miyake, N., Nakajima, H., Saitsu, H., Miyatake, S., and Matsumoto, N.

Published
2018
Full Text
View/download PDF

22. Size in development

Author

MORIMOTO, M., HAYASHI, S., INOMATA, H., PICCOLO, S., Hayashi, Shigeo, Morimoto, Mitsuru, Inomata, Hidehiko, and Piccolo, Stefano

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results